Your browser doesn't support javascript.
loading
Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells.
Xu, Nan; Yang, Xiao-Fei; Xue, Sheng-Li; Tan, Jing-Wen; Li, Ming-Hao; Ye, Jing; Lou, Xiao-Yan; Yu, Zhou; Kang, Li-Qing; Yan, Zhi-Qiang; Yu, Lei; Chen, Su-Ning; Wang, Yi-Ting.
Afiliación
  • Xu N; Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.
  • Yang XF; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Xue SL; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Tan JW; Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.
  • Li MH; Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.
  • Ye J; Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China.
  • Lou XY; Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China.
  • Yu Z; Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China.
  • Kang LQ; Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China.
  • Yan ZQ; Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.
  • Yu L; Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China; Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shangha
  • Chen SN; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. Electronic
  • Wang YT; Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China. Electronic address: ytwang@nbic.ecnu.edu.cn.
Biochem Biophys Res Commun ; 595: 54-61, 2022 03 05.
Article en En | MEDLINE | ID: mdl-35101664
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pirazoles / Pirimidinas / Linfocitos T / Proliferación Celular / Receptores Quiméricos de Antígenos / Síndrome de Liberación de Citoquinas / Nitrilos Límite: Animals / Humans / Male Idioma: En Revista: Biochem Biophys Res Commun Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pirazoles / Pirimidinas / Linfocitos T / Proliferación Celular / Receptores Quiméricos de Antígenos / Síndrome de Liberación de Citoquinas / Nitrilos Límite: Animals / Humans / Male Idioma: En Revista: Biochem Biophys Res Commun Año: 2022 Tipo del documento: Article País de afiliación: China